Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study

Abstract

Selinexor is a first-in-class, oral therapy that selectively inhibits nuclear export. The drug is active with an overall response rate (ORR) of approximately 30% in relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL). Long-term patient follow-up has not been reported. Thirty-one NHL patients were treated between July 2012 and July 2018; 22 were evaluated for response. ORR was 32% (7/22). Two patients achieved complete remission (CR) and were alive and lymphoma-free at the end of follow-up. Fifteen patients (68%) progressed during treatment, most of them died within 3–10 months. The most common grade 3/4 adverse events were gastrointestinal and hematological. Median follow up was 50 months. Overall survival for the entire cohort was 16%. Selinexor monotherapy for r/r NHL is an active therapy with the potential for long-term disease control. It may serve as a ‘bridge’ to subsequent therapy. Additional studies are needed to identify predictive biomarkers and to evaluate combination approaches.

Keywords:

• Selinexor
• KPT-330
• XPO1
• non-Hodgkin lymphoma (NHL)

Disclosure statement

AP has received consulting fee from Astra-Zenca and Kite-Gilead. JK has received honoraria from AbbVie, Bristol Myers Squibb, Amgen, AstraZeneca, Celgene, Gilead Sciences, Janssen, Karyopharm Therapeutics, Merck, Novartis, Roche, and Seattle Genetics; has consultancy or advisory roles with AbbVie, Bristol Myers Squibb, Gilead Sciences, Karyopharm Therapeutics, Merck, Roche/Genentech, and Seattle Genetics; has DSMB membership with Karyopharm and has received research grants or funding from Janssen and Roche. MC has received consulting fee from Kyte Gilead and Novartis and is member in the board of director of the Canadian Partnership Against Cancer. RK has received grants from Gilead Science and Roche. SB has received honoraria from Celgene and Sanofi; has consultancy role with Bristol-Myers Squibb. SBB: no conflicts. VK has received Honoria from Kyora Kirin, Celgene and Amgen.